Tricyclic protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
AssigneeHeparegenix GmbH
InventorsMichael JUCHUM, Roland SELIG, Stefan LAUFER, Wolfgang ALBRECHT
Life of this patent
Estimating the term…
Abstract
The invention relates to tricyclic compounds which are MKK4 (mitogen-activated protein kinase kinase 4) inhibitors which selectively inhibit protein kinase kinase MKK4 over protein kinases JNK and MKK7. They are useful for promoting liver regeneration or reducing or preventing hepatocyte death.
Claims17
A compound having formula (I) and the pharmaceutically acceptable salts, solvates and optical isomers thereof,
- wherein the variables in formula (I) have the meanings as follows:
- R1 is H or alkyl;
- R2 is H or alkyl;
- R3 is H or alkyl;
- Q is phenyl, which is substituted with Ra and is optionally substituted with Rb, Rc, Rd and Re;
- Ra is —NR10SO2R12, —NR10SO2NR10R12 or —N═S(═O)R10NR10R10;
- Rb, Rc, Rd and Re are independently selected from
- a) H,
- b) alkyl which is optionally substituted with 1 or 2 substituents independently selected from phenyl, halogen substituted phenyl, halogen, OH, CN, and —NR10R10, and
- c) halogen,
- wherein at least one of Rb, Rc, Rd and Re is halogen
- R4 is H or alkyl;
- R5 is selected from
- a) halogen;
- b) phenyl or naphthyl which phenyl or naphthyl is optionally substituted with 1, 2 or 3 groups independently selected from halogen, hydroxy, R11O—, —COOR10, R10OCO—, R10R10N—CO—, R10R11NSO2—, and a heteroaromatic 5- or 6-membered monocyclic or heteroaromatic 9- or 10-membered bicyclic group having 1, 2, 3 or 4 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen, —NR10R10, and alkyl which is optionally substituted with 1, 2 or 3 hydroxy groups, and
- c) a heteroaromatic 5- or 6-membered monocyclic or heteroaromatic 9- or 10-membered bicyclic group having 1 to 3 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from —NR10R10, R10R11N—SO2—, R10R11N—CO— and a heteroaromatic 5- or 6-membered group having 1 or 2 heteroatoms independently selected from O, N and S which group is optionally substituted with 1 or 2 groups independently selected from alkyl, alkoxy, halogen, —NR10R10, and alkyl which is optionally substituted with 1, 2 or 3 hydroxy groups;
- R6 is H or alkyl;
- R10 at each occurrence independently is H, alkyl, phenyl, which is optionally substituted with 1 or 2 hydroxyl or alkoxy groups, or is phenylalkyl wherein the phenyl group is optionally substituted with halogen or alkyl;
- R11 is H, or alkyl, which is optionally substituted with 1 or 2 hydroxy groups;
- R12 is
- alkyl, which is optionally substituted with 1 or 2 groups independently selected from halogen, phenyl and cycloalkyl,
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, having formula
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims having formula (Ib) or (Ic)
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein
- R5 is selected from
- a) halogen,
- b) phenyl which is optionally substituted with 1 or 2 groups independently selected from halogen, hydroxy, R11O—, COOR10, R10R10N—CO—, R10R11NSO2—, and tetrazolyl, and
- c) pyridyl which is optionally substituted with 1 or 2 groups independently selected from —NR10R10, R10R11N—SO2—, R10R11N—CO— and pyrrolyl which is optionally substituted with 1 or 2 alkyl groups.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein Ra is —NR10SO2R12, and R12 is alkyl.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein
- a) Rb and Re are both halogen, in particular fluorine, or
- b) Rb and Rc are both halogen, in particular fluorine.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R1, R2, R3, R4, and R6 are H.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R10 is H or alkyl.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, wherein R11 is alkyl, in particular C2-, C3- or C4-alkyl.
The compound and the pharmaceutically acceptable salts, solvates and optical isomers thereof, of any one of the preceding claims, selected from the group consisting of
Dependencies are inferred from the claim text.